Streetbeat News

AMLX

Amylyx Pharmaceuticals, Inc.

Industry

Biotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Open

5.33

Mkt cap

367M

Volume

186K

High

5.38

P/E Ratio

-1.40

52-wk high

19.95

Low

5.15

Div yield

N/A

52-wk low

1.57

Amylyx Pharmaceuticals, Inc. (AMLX) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 09, 2024 | 3:15 pm

HC Wainwright & Co. has reiterated its Buy rating for Amylyx Pharma, maintaining a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 10:35 am

Amylyx Pharmaceuticals announced positive topline results from its Phase 2 HELIOS trial for AMX0035 in treating Wolfram Syndrome. The trial showed sustained improvements in pancreatic function and stabilization across secondary endpoints. The company plans to proceed with Phase 3 trials and FDA discussions in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:02 pm

Insider buying activity has been observed in three penny stocks: Exicure, Amylyx Pharmaceuticals, and Reneo Pharmaceuticals. This insider activity may indicate confidence in the companies' prospects.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 1:01 pm

Amylyx Pharmaceuticals announced the publication of data from the Phase 2 PEGASUS trial, showing that their drug AMX0035 affects cerebrospinal fluid biomarkers related to Alzheimer's disease and neurodegeneration. The findings were published in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:06 pm

Amylyx Pharma (NASDAQ:AMLX) reported Q2 2024 adjusted EPS of $(0.73), which met analyst expectations. However, the company reported quarterly sales of $(1.203 million), significantly missing the analyst consensus estimate of $10.663 million and representing a 101.22% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:15 am

Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for its drug AMX0035, aimed at treating Wolfram Syndrome. The company expects topline data from its Phase 2 HELIOS trial in Fall 2024.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:01 pm

Top Wall Street analysts have updated their price targets and ratings for several major companies. Notable changes include Piper Sandler cutting Adobe's price target, Needham slashing KalVista Pharmaceuticals' target, Baird lowering Visteon's target, Deutsche Bank increasing Block's target, Goldman Sachs boosting Amylyx Pharmaceuticals' target, Bernstein cutting Delta Air Lines' target, Benchmark increasing NVIDIA's target, TD Cowen raising Costco's target, Mizuho boosting Tesla's target, and Oppenheimer raising NXP Semiconductors' target.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 12:18 pm

Six analysts have recently shared their insights on Amylyx Pharma (NASDAQ:AMLX), with ratings ranging from bullish to bearish. The average 12-month price target is $6.33, with a high of $8.00 and a low of $3.00. Recent actions include maintaining 'Buy' ratings and lowering 'Neutral' ratings.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 12:00 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 10:22 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.